<DOC>
	<DOCNO>NCT02516774</DOCNO>
	<brief_summary>The hypothesis particular richness ATC 's microenvironment TAMs create unique opportunity use Tumor Necrosis Factor blockade chemotherapy radiotherapy order counteract tumor resistance therapy .</brief_summary>
	<brief_title>A Trial Adalimumab Combined Chemotherapy Radiotherapy Patients With Anaplastic Thyroid Cancers</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Pathologically proven anaplastic thyroid cancer ( localize metastatic ) 2 . Lifeexpectancy &gt; 12 week 3 . No previous treatment anaplastic thyroid cancer except surgery crizotinib 4 . Written Informed consent sign 5 . Age &gt; 18 year 6. WHO 03 7 . Neutrophil count &gt; 1500 /mm3 , Haemoglobin &gt; 9 gr/dL , Platelet count &gt; 100,000/mm3 8 . Bilirubin &lt; 1.5 mg/dL , Transaminases &lt; 3 N absence liver metastases &lt; 5 N presence liver metastasis , PT &gt; 70 % 9 . Creatinine clearance &gt; 50ml/mn ( calculate MDRD formula ) 10 . Negative pregnancy test woman childbearing potential within 14 day prior treatment initiation ( premenopausal le 12 month amenorrhea postmenopause , undergone surgical sterilization ) . Both men woman ( childbearing potential ) sexually active , must use adequate contraception , least 6 month posttreatment . 11 . Evaluable disease &gt; 1 cm within cervicomediastinal field radiotherapy accord Response Evaluation Criteria Solid Tumors 1.1 criterion 12 . Patient affiliate social security regimen beneficiary regimen 1 . Prior treatment anthracyclines 2 . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % 3 . Known allergy Adalimumab , doxorubicin , cisplatin , carboplatin paclitaxel 4 . Chronic acute infection &lt; 15 day 5 . Pregnant breastfeeding patient 6 . Any malignancy past 5 year except basal cell carcinoma carcinoma situ cervix 7 . Previous and/or active demyelinating disease , multiple sclerosis 8 . Prior radiotherapy neck 9 . Concomitant therapy agent otherwise use treatment cancer ( example methotrexate rheumatoid arthritis ) 10 . Chronic ( &gt; 3 month ) treatment oral corticosteroid another immunosuppressant within 15 day prior registration 11 . Patients active bleeding diathesis take oral vitamin K antagonist ( except lowdose Coumadin ( warfarin sodium ) ) 12 . Other concurrent severe and/or uncontrolled disease could compromise participation study ( i.e . uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , unstable angina , congestive heart failure New York Heart Association Class III IV , ventricular arrhythmia , active ischemic heart disease , myocardial infarction previous six month , chronic liver renal disease , active upper GI tract ulceration ) 13 . Patient already enrol another therapeutic trial involve investigational substance , substance take previous 4 week 14 . Chronic Hepatitis B virus previous viral hepatitis risk reactivation , Hepatitis C virus human immunodeficiency virus 1 human immunodeficiency virus 2 infection , active latent tuberculosis infection 15 . Persons deprive freedom guardianship , would impossible undergo medical followup require trial , geographic , social psychological reason Refusal absence biopsy ( excepted initial pathological diagnosis ) constitute exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>